Considerable evidence supports the idea that NLRP3 inflammasome plays a pro-inflammatory role in colitis pathology [36,37,38,39], and blockage of IL-1β [27,40] or IL-18 [41] has been reported to reduce colitis. Here, IL18 is linked to colitis.